Is Prediabetes a Risk Factor for Neuropathy?
by Dr. Richard Mann, DABPS, ret, Chief Scientific Officer & Founder, Realm Labs®
According to the American Diabetes Association, before people develop type 2 diabetes, they almost always have “prediabetes” — blood glucose levels that are higher than normal but not yet high enough to be diagnosed as diabetes. Also known as impaired glucose tolerance (IGT), prediabetes is a hidden epidemic by any definition. In 2015, according to the CDC, 84 million people in the US were prediabetic and 90% of those were unaware that they had it. Since its pathogenesis is a consequence early glucose dysregulation, it would be reasonable to expect that the earliest and most common complication of diabetes, polyneuropathy, would be more frequent in prediabetics than in non-diabetics…and that, in fact, turns out to be the case.
A research group in the UK, after a comprehensive literature review, recently published a paper in the journal Diabetes reporting an estimated 18% prevalence of peripheral neuropathy in prediabetics. A Canadian study found the prevalence of neuropathy in prediabetes to be about the same as in newly diagnosed diabetics. The neuropathy associated with prediabetes is clinically similar to early diabetic neuropathy, with preferential injury to small nerve fibers resulting in pain and autonomic dysfunction. Surprisingly, many clinicians are unaware that prediabetes is an independent risk factor for polyneuropathy. A recent study found that 40% of all patients diagnosed with idiopathic neuropathy actually had prediabetes.
The treatment for prediabetic and diabetic polyneuropathy are basically the same - lifestyle changes including improved diet and exercise, protecting the feet and legs from injury, appropriate nutrients such as benfotiamine, vitamins B6, 9 and 12, essential fatty acids, Alpha Lipoic Acid, etc., physical therapy, topical analgesics and, if necessary, the use antidepressants and anticonvulsants to manage extreme symptoms.
Dr. Richard H Mann, DABPS, ret
Chief Scientific Officer & Founder, Realm Labs
If you would like to speak with Dr. Mann about how to improve your outcomes in the treatment of polyneuropathy call 561-549-9099 or email Dr. Mann at firstname.lastname@example.org.
Dr. Mann is the developer of the NeuRemedy® line of benfotiamine nutritional supplements. NeuRemedy is a safe, proven, and effective nutritional formulation dispensed by physicians to their patients suffering from numbness, tingling, burning and/or shooting pains in the feet and legs. These symptoms are commonly associated with diabetes, prediabetes, advanced age, chronic alcohol consumption, and chemotherapy. Thiamine (vitamin B1) deficiency often accompanies and intensifies these symptoms. The reversal of thiamine deficiency is an important therapeutic goal in the management of these patients.*
The key ingredient in NeuRemedy, benfotiamine, is the most highly bioactive oral form of thiamine available. It rapidly and safely reverses thiamine deficiency, improving the functioning of the nerves in the feet and legs. Each capsule of NeuRemedy contains 150 mg of benfotiamine in a proprietary formulation. Because of its impressive success rate and high safety profile, NeuRemedy was recently licensed in Canada as an important factor in supporting healthy nerve function in individuals with polyneuropathy.* NeuRemedy is the leader in the field with thousands of physicians and patients relying each day on its efficacy, purity, safety and rapid onset of action.*
For information NeuRemedy contact Realm Labs at 866-634-2745.
In Canada contact OHI at 855-561-4156.